Abdera Therapeutics
Alex Mandel is an experienced chemist specializing in synthetic chemistry for targeted radiopharmaceuticals. Currently serving as the Director of Chemistry at Abdera Therapeutics since January 2024, Mandel previously held the role of Senior Scientist at the same organization and led various synthetic chemistry programs. Prior experience includes key positions at adMare BioInnovations, where leadership in new targeted alpha therapy and radioconjugate research took place, and at The Centre for Drug Research & Development, contributing to novel technologies in antibody-drug conjugates and radioimmunotherapy. Academic credentials include a PhD in Organic Chemistry from UC San Diego and a BS in Chemistry from Harvey Mudd College.
Abdera Therapeutics
1 followers
Abdera is an oncology company developing targeted alpha therapies (TATs) for patients with relapsed, refractory, and metastatic cancers. Its targeted radiotherapies utilize purpose-built vectors to specifically target high-energy radio-isotopes to tumors and metastatic cancer lesions. This new class of drugs holds tremendous untapped therapeuticand commercial potential, and has generated over $10B in recent M&A, financings, and product launches – and are expected to comprise 70% of the $30B nuclear medicine market by 2030.It was launched by adMare BioInnovations, Canada’s global life sciences venture, in partnership with industry leaders AbCellera, and some of the country’s most successful scientist entrepreneurs.